New science & innovation business unit to advance aurora's leadership in biosynthesis and plant genetics

The company's patented technology expected to be key to commercial success in cannabinoid biosynthesis nasdaq | tsx: acb edmonton, ab, may 27, 2021 /prnewswire/ - aurora cannabis inc. (nasdaq: acb) (tsx: acb), the canadian company defining the future of cannabinoids worldwide, announced today the launch of a dedicated science & innovation business group, with the aim of commercializing patented and patent pending technology that the company believes will be key in the development of cannabinoid biosynthesis and plant genetics.   aurora's connection to the biosynthetic production of cannabinoids originated with early work carried out by the company's former chief science officer on the discovery of key genes within the cannabinoid biosynthesis pathway.
ACB Ratings Summary
ACB Quant Ranking